Top Markets
#1 Black Phoenix Black Phoenix +733.82%
#2 MiL.k Alliance MiL.k Alliance +29.84%
#3 Biconomy Biconomy +24.27%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.03%
#5 THORChain THORChain +19.51%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +15.95%
#7 Moolah Moolah +14.73%
#8 THORChain Yield THORChain Yield +14.31%
#9 Tokamak Network Tokamak Network +12.76%
#10 XPIN Network XPIN Network +12.32%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Hybio Pharmaceutical Co., Ltd. Hybio Pharmaceutical Co., Ltd.

Hybio Pharmaceutical Co., Ltd.

300199
Peringkat dalam Saham #5169
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Harga Saham
$3.32
Kapitalisasi Pasar
$2.93B
Perubahan (1 hari)
1.10%
Perubahan (1 tahun)
-8.99%
Negara
CN
Perdagangan Hybio Pharmaceutical Co., Ltd. (300199)

Kategori

Healthcare
Pendapatan untuk Hybio Pharmaceutical Co., Ltd. (300199)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari Hybio Pharmaceutical Co., Ltd., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Hybio Pharmaceutical Co., Ltd. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN